Ventyx Biosciences is a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high-value targets. Ventyx now includes combined assets from three separate companies: Oppilan Pharma, targeting S1P1R, Zomagen Biosciences, targeting NLRP3 and the inflammasome, and Ventyx Biosciences, targeting TYK2.

Biotechnology

Ventyx Biosciences

Raju Mohan

Deepika Kalyanam

Naomi Lyon

Ruchi Patel

Elaine Law, CCDM

Andria Tsang Hambly

Nada Mitic

Kye Gilder

Snehal Naik

John Nuss

Chris Krueger

Martin D. Auster

Business Operations

R&D and Clinical Operations

Advisory Team

Clinical Data Management Team

Finance and Accounting Team

Leadership Team

Quality Assurance and Regulatory Affairs

Teams at Ventyx Biosciences